Molecular Cancer Therapeutics 影响因子、索引、排名

Molecular Cancer Therapeutics 是一本致力于发表该领域研究成果的学术期刊 Medicine. American Association for Cancer Research 是这本受人尊敬的期刊的出版商。. P-ISSN 分配给 Molecular Cancer Therapeutics 是 1535-7163 它的缩写形式是 Mol Cancer Ther.

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.

The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts:

Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly. Sufficient detail is provided to facilitate repetition of the experiments to verify data. Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies. Appropriate replicates in cellular studies are used. Relevant cell lines, animal models, and assays are utilized. Studies must be performed according to AACR and Institutional Guidelines. Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions. Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies. Appropriate controls are employed for all experiments (especially inactive analog compounds). In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated. Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered. For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material. Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.

Molecular Cancer Therapeutics 缩写 : 期刊缩写是指用于表示学术期刊完整标题的缩写形式或首字母缩略词。 它是一种常用的速记方式，有助于在学术出版物、参考书目和数据库中引用、索引和引用期刊。

的缩写 Molecular Cancer Therapeutics 是 Mol Cancer Ther

Molecular Cancer Therapeutics 排行 : 期刊排名是指对学术期刊进行评估和分类的过程 (Molecular Cancer Therapeutics) 基于各种标准，例如影响因子、引用指标、专家评估和其他指标。 排名系统旨在提供期刊在特定领域或学科内的质量、影响力和声望的指示。

的排名 Molecular Cancer Therapeutics 是 1088 (2025)

Molecular Cancer Therapeutics 影响因子 : 影响因子是用来评估学术期刊在各自领域内的影响力和重要性的指标。 它通常每年计算一次，衡量特定时期内期刊上发表的文章收到的平均引用次数。

影响因子 Molecular Cancer Therapeutics 是 5.7 (2025)

Molecular Cancer Therapeutics SCImago : SCImago 期刊排名 (SJR) 是由 SCImago Lab 开发的指标和数据库，提供有关学术期刊的科学影响力和声望的信息。 SCImago 是一个位于西班牙的独立研究小组，专注于科学期刊的文献计量分析和排名。

的SCImagoMolecular Cancer Therapeutics 是 1.890

Molecular Cancer Therapeutics H指数 : 期刊 H 指数是根据学术期刊的出版物以及这些出版物获得的引用次数来衡量学术期刊的影响力和影响力的指标。 它源自作者 h 指数的概念，该指数根据单个研究人员被引用次数最多的论文来评估其影响力。

H 指数 Molecular Cancer Therapeutics 是 190

Molecular Cancer Therapeutics 索引 : 期刊索引是指将期刊纳入对学术出版物进行分类和组织的可搜索数据库或索引的过程。 索引服务旨在使研究人员、学者和读者更轻松地发现和访问特定领域或学科内各种期刊的文章。

这 Molecular Cancer Therapeutics 这 索引于

• Web of Science
• UGC
• Scopus
• PubMed
• ProQuest
• Medline
• Google Scholar
• BIOSIS Previews

被索引的期刊表明它已经过期刊索引者的彻底审查过程，以满足特定的标准和要求。

Molecular Cancer Therapeutics 提交费 : 文章提交费，也称为稿件提交费或处理费，是一些期刊向提交研究论文以供考虑出版的作者收取的费用。 这些费用与可能与接受的稿件相关的任何出版费或文章处理费 (APC) 是分开的。

提交费 Molecular Cancer Therapeutics 是 Base Fee, $1900, OA Price $6000

• Journal Website
• PubMed
• Scopus
• SCImago